Here, we demonstrated that combining KRAS inhibitors with gemcitabine effectively overcomes the resistance phenotype associated with CDKN2A loss, highlighting a potential therapeutic strategy for this resistant subset of KRAS-mutant pancreatic cancer. Here, KRAS is linked to pancreatic neoplasm.